VNDA logo

Vanda Pharmaceuticals (VNDA) Cash From Operations

Annual CFO

-$15.76 M
-$28.56 M-223.09%

December 31, 2024

Summary

Performance

1-Year Change

-223.09%

3-Year Change

-124.54%

5-Year Change

-134.29%

15-Year Change

-694.6%

VNDA Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

50.83%
VNDA annual cash flow from operations is higher than 50.83% of companies in Healthcare sector

High & Low

All-time High

$169.34 M
VNDA annual cash flow from operations is currently -109.31% below its historical high of $169.34 million

3-Year Low

-$15.76 M
VNDA annual cash flow from operations is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
VNDA previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
VNDA next annual earnings announcement has not yet been scheduled

OtherVNDAcash flowmetrics:

Annual CFI

-$17.43 M
VNDA annual cash flow from investing activities is -$17.43 million

Annual CFF

-$155.00 K
VNDA annual cash flow from financing activities is -$155.00 thousand

Annual FCF

-$16.25 M
VNDA annual free cash flow is -$16.25 million

Annual CAPEX

$490.00 K
VNDA annual capital expenditures is $490.00 thousand

Quarterly CFO

-$1.82 M
+$12.76 M+87.54%

December 31, 2024

Summary

Performance

3-Month Change

+87.54%

1-Year Change

-124.01%

3-Year Change

-124.01%

5-Year Change

-124.01%

VNDA Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

62.07%
VNDA quarterly cash flow from operations is higher than 62.07% of companies in Healthcare sector

High & Low

All-time High

$189.29 M
VNDA quarterly cash flow from operations is currently -100.96% below its historical high of $189.29 million

3-Year Low

-$14.58 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
VNDA previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 8, 2025
VNDA next earnings announcement is scheduled for May 8, 2025

OtherVNDAcash flowmetrics:

Quarterly CFI

$3.99 M
VNDA quarterly cash flow from investing activities is $3.99 million

Quarterly CFF

-
VNDA quarterly cash flow from financing activities value is unknown

Quarterly FCF

-$2.03 M
VNDA quarterly free cash flow is -$2.03 million

Quarterly CAPEX

$214.00 K
VNDA quarterly capital expenditures is $214.00 thousand

TTM CFO

-$15.76 M
+$1.92 M+10.84%

December 31, 2024

Summary

Performance

3-Month Change

+10.84%

1-Year Change

-37.82%

3-Year Change

-37.82%

5-Year Change

-37.82%

VNDA TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

50.49%
VNDA TTM cash flow from operations is higher than 50.49% of companies in Healthcare sector

High & Low

All-time High

$183.49 M
VNDA TTM cash flow from operations is currently -108.59% below its historical high of $183.49 million

3-Year Low

-$17.67 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
VNDA previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 8, 2025
VNDA next earnings announcement is scheduled for May 8, 2025

OtherVNDAcash flowmetrics:

TTM CFI

-$17.43 M
VNDA TTM cash flow from investing activities is -$17.43 million

TTM CFF

-
VNDA TTM cash flow from financing activities value is unknown

TTM FCF

-$16.25 M
VNDA TTM free cash flow is -$16.25 million

TTM CAPEX

$490.00 K
VNDA TTM capital expenditures is $490.00 thousand

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

VNDA Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-223.1%-124.0%-37.8%
3 y3 years-124.5%-124.0%-37.8%
5 y5 years-134.3%-124.0%-37.8%

VNDA Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-124.5%at low-105.7%+87.5%-124.5%+10.8%
5 y5-year-124.5%at low-105.7%+87.5%-124.5%+10.8%
alltimeall time-109.3%+80.7%-101.0%+95.0%-108.6%+81.0%

Vanda Pharmaceuticals Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-$15.76 M(-223.1%)
-$1.82 M(-87.5%)
-$15.76 M(-10.8%)
Sep 2024
-
-$14.58 M(+110.5%)
-$17.67 M(+243.7%)
Jun 2024
-
-$6.93 M(-191.5%)
-$5.14 M(-55.0%)
Mar 2024
-
$7.57 M(-302.8%)
-$11.43 M(-189.3%)
Dec 2023
$12.80 M(-60.0%)
-$3.73 M(+82.0%)
$12.80 M(-50.7%)
Sep 2023
-
-$2.05 M(-84.5%)
$25.95 M(-36.5%)
Jun 2023
-
-$13.22 M(-141.6%)
$40.84 M(-31.6%)
Mar 2023
-
$31.80 M(+237.8%)
$59.74 M(+86.8%)
Dec 2022
$31.98 M(-50.2%)
$9.42 M(-26.6%)
$31.98 M(-35.0%)
Sep 2022
-
$12.84 M(+125.8%)
$49.17 M(+7.5%)
Jun 2022
-
$5.68 M(+40.5%)
$45.73 M(-22.6%)
Mar 2022
-
$4.05 M(-84.8%)
$59.07 M(-8.0%)
Dec 2021
$64.21 M(+24.0%)
$26.61 M(+183.1%)
$64.21 M(+12.8%)
Sep 2021
-
$9.40 M(-50.6%)
$56.91 M(+0.0%)
Jun 2021
-
$19.02 M(+106.9%)
$56.89 M(-8.1%)
Mar 2021
-
$9.19 M(-52.4%)
$61.88 M(+19.5%)
Dec 2020
$51.77 M(+12.7%)
$19.30 M(+105.9%)
$51.77 M(+22.5%)
Sep 2020
-
$9.37 M(-61.0%)
$42.26 M(+8.7%)
Jun 2020
-
$24.01 M(-2746.7%)
$38.89 M(+9.9%)
Mar 2020
-
-$907.00 K(-109.3%)
$35.40 M(-23.0%)
Dec 2019
$45.95 M(+53.2%)
$9.79 M(+63.2%)
$45.95 M(-10.6%)
Sep 2019
-
$6.00 M(-70.8%)
$51.42 M(-5.0%)
Jun 2019
-
$20.52 M(+112.7%)
$54.12 M(+42.4%)
Mar 2019
-
$9.64 M(-36.8%)
$37.99 M(+26.7%)
Dec 2018
$29.99 M(-1612.2%)
$15.26 M(+75.6%)
$29.99 M(+64.9%)
Sep 2018
-
$8.69 M(+98.0%)
$18.19 M(+56.0%)
Jun 2018
-
$4.39 M(+168.1%)
$11.66 M(+132.7%)
Mar 2018
-
$1.64 M(-52.7%)
$5.01 M(-352.7%)
Dec 2017
-$1.98 M(-75.5%)
$3.47 M(+59.9%)
-$1.98 M(-70.1%)
Sep 2017
-
$2.17 M(-195.9%)
-$6.63 M(-12.3%)
Jun 2017
-
-$2.26 M(-57.8%)
-$7.56 M(-11.7%)
Mar 2017
-
-$5.36 M(+352.8%)
-$8.56 M(+5.7%)
Dec 2016
-$8.10 M(-165.1%)
-$1.18 M(-195.3%)
-$8.10 M(+11.4%)
Sep 2016
-
$1.24 M(-138.0%)
-$7.28 M(-45.6%)
Jun 2016
-
-$3.26 M(-33.4%)
-$13.37 M(-770.1%)
Mar 2016
-
-$4.90 M(+1276.1%)
$2.00 M(-84.0%)
Dec 2015
$12.45 M(-115.3%)
-$356.00 K(-92.7%)
$12.45 M(-2242.7%)
Sep 2015
-
-$4.85 M(-140.1%)
-$581.00 K(-82.5%)
Jun 2015
-
$12.10 M(+117.8%)
-$3.33 M(-93.6%)
Mar 2015
-
$5.55 M(-141.5%)
-$52.09 M(-36.1%)
DateAnnualQuarterlyTTM
Dec 2014
-$81.55 M(+106.0%)
-$13.39 M(+76.2%)
-$81.55 M(+1.5%)
Sep 2014
-
-$7.60 M(-79.3%)
-$80.32 M(-3.2%)
Jun 2014
-
-$36.66 M(+53.4%)
-$82.99 M(+52.6%)
Mar 2014
-
-$23.90 M(+96.7%)
-$54.37 M(+37.3%)
Dec 2013
-$39.59 M(-11.9%)
-$12.15 M(+18.3%)
-$39.59 M(-4.1%)
Sep 2013
-
-$10.27 M(+27.7%)
-$41.29 M(+0.3%)
Jun 2013
-
-$8.04 M(-11.9%)
-$41.18 M(-9.2%)
Mar 2013
-
-$9.13 M(-34.1%)
-$45.35 M(+1.0%)
Dec 2012
-$44.92 M(+58.1%)
-$13.85 M(+36.3%)
-$44.92 M(+3.4%)
Sep 2012
-
-$10.16 M(-16.8%)
-$43.42 M(+7.4%)
Jun 2012
-
-$12.21 M(+40.6%)
-$40.43 M(+19.5%)
Mar 2012
-
-$8.69 M(-29.7%)
-$33.84 M(+19.1%)
Dec 2011
-$28.41 M(+160.7%)
-$12.36 M(+72.3%)
-$28.41 M(+34.3%)
Sep 2011
-
-$7.17 M(+27.6%)
-$21.15 M(+11.0%)
Jun 2011
-
-$5.62 M(+72.2%)
-$19.05 M(+104.1%)
Mar 2011
-
-$3.26 M(-35.9%)
-$9.34 M(-14.3%)
Dec 2010
-$10.90 M(-106.4%)
-$5.10 M(+0.4%)
-$10.90 M(-105.9%)
Sep 2010
-
-$5.07 M(-223.8%)
$183.49 M(+2.0%)
Jun 2010
-
$4.10 M(-184.9%)
$179.85 M(+6.9%)
Mar 2010
-
-$4.83 M(-102.5%)
$168.30 M(-0.6%)
Dec 2009
$169.34 M(-468.5%)
$189.29 M(-2272.2%)
$169.34 M(-766.5%)
Sep 2009
-
-$8.71 M(+17.0%)
-$25.41 M(-15.3%)
Jun 2009
-
-$7.45 M(+96.2%)
-$29.98 M(-10.9%)
Mar 2009
-
-$3.79 M(-30.4%)
-$33.64 M(-26.8%)
Dec 2008
-$45.96 M(-11.0%)
-$5.45 M(-59.0%)
-$45.96 M(-19.6%)
Sep 2008
-
-$13.29 M(+19.6%)
-$57.13 M(+4.5%)
Jun 2008
-
-$11.11 M(-31.0%)
-$54.65 M(+0.6%)
Mar 2008
-
-$16.11 M(-3.1%)
-$54.35 M(+5.2%)
Dec 2007
-$51.64 M(+0.0%)
-$16.62 M(+53.7%)
-$51.64 M(+11.9%)
Sep 2007
-
-$10.82 M(+0.1%)
-$46.14 M(-11.7%)
Jun 2007
-
-$10.80 M(-19.4%)
-$52.24 M(-3.8%)
Mar 2007
-
-$13.41 M(+20.6%)
-$54.31 M(+5.2%)
Dec 2006
-$51.62 M(+191.4%)
-$11.12 M(-34.3%)
-$51.62 M(+11.2%)
Sep 2006
-
-$16.92 M(+31.6%)
-$46.40 M(+36.5%)
Jun 2006
-
-$12.86 M(+20.0%)
-$34.01 M(+36.9%)
Mar 2006
-
-$10.72 M(+81.6%)
-$24.84 M(+40.2%)
Dec 2005
-$17.71 M(+105.6%)
-$5.90 M(+30.3%)
-$17.71 M(+50.0%)
Sep 2005
-
-$4.53 M(+22.7%)
-$11.81 M(+62.1%)
Jun 2005
-
-$3.69 M(+2.7%)
-$7.29 M(+102.7%)
Mar 2005
-
-$3.59 M
-$3.59 M
Dec 2004
-$8.61 M
-
-

FAQ

  • What is Vanda Pharmaceuticals annual cash flow from operations?
  • What is the all time high annual CFO for Vanda Pharmaceuticals?
  • What is Vanda Pharmaceuticals annual CFO year-on-year change?
  • What is Vanda Pharmaceuticals quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Vanda Pharmaceuticals?
  • What is Vanda Pharmaceuticals quarterly CFO year-on-year change?
  • What is Vanda Pharmaceuticals TTM cash flow from operations?
  • What is the all time high TTM CFO for Vanda Pharmaceuticals?
  • What is Vanda Pharmaceuticals TTM CFO year-on-year change?

What is Vanda Pharmaceuticals annual cash flow from operations?

The current annual CFO of VNDA is -$15.76 M

What is the all time high annual CFO for Vanda Pharmaceuticals?

Vanda Pharmaceuticals all-time high annual cash flow from operations is $169.34 M

What is Vanda Pharmaceuticals annual CFO year-on-year change?

Over the past year, VNDA annual cash flow from operations has changed by -$28.56 M (-223.09%)

What is Vanda Pharmaceuticals quarterly cash flow from operations?

The current quarterly CFO of VNDA is -$1.82 M

What is the all time high quarterly CFO for Vanda Pharmaceuticals?

Vanda Pharmaceuticals all-time high quarterly cash flow from operations is $189.29 M

What is Vanda Pharmaceuticals quarterly CFO year-on-year change?

Over the past year, VNDA quarterly cash flow from operations has changed by -$9.39 M (-124.01%)

What is Vanda Pharmaceuticals TTM cash flow from operations?

The current TTM CFO of VNDA is -$15.76 M

What is the all time high TTM CFO for Vanda Pharmaceuticals?

Vanda Pharmaceuticals all-time high TTM cash flow from operations is $183.49 M

What is Vanda Pharmaceuticals TTM CFO year-on-year change?

Over the past year, VNDA TTM cash flow from operations has changed by -$4.32 M (-37.82%)